206 related articles for article (PubMed ID: 37419495)
1. Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry.
Stolfo D; Lund LH; Benson L; Lindberg F; Ferrannini G; Dahlström U; Sinagra G; Rosano GMC; Savarese G
Eur J Heart Fail; 2023 Sep; 25(9):1648-1658. PubMed ID: 37419495
[TBL] [Abstract][Full Text] [Related]
2. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
Eur J Heart Fail; 2021 Jun; 23(6):1012-1022. PubMed ID: 33599357
[TBL] [Abstract][Full Text] [Related]
3. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry.
Pierce JB; Vaduganathan M; Fonarow GC; Ikeaba U; Chiswell K; Butler J; DeVore AD; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; Linganathan KK; McDermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Greene SJ
JAMA Cardiol; 2023 Jul; 8(7):652-661. PubMed ID: 37212192
[TBL] [Abstract][Full Text] [Related]
4. Dapagliflozin in a Real-World Chronic Heart Failure Population: How Many Are Actually Eligible?
Maltês S; Cunha GJL; Rocha BML; Presume J; Guerreiro R; Henriques C; Rodrigues C; Araújo I; Fonseca C
Cardiology; 2021; 146(2):201-206. PubMed ID: 33524984
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
Mentz RJ; Brunton SA; Rangaswami J
Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
[TBL] [Abstract][Full Text] [Related]
6. Cardio-renal-metabolic syndrome: clinical features and dapagliflozin eligibility in a real-world heart failure cohort.
Beles M; Masuy I; Verstreken S; Bartunek J; Dierckx R; Heggermont W; Oeste C; De Boeck M; Fovel I; Maris M; Vermeulen Z; Vanderheyden M
ESC Heart Fail; 2023 Aug; 10(4):2269-2280. PubMed ID: 37095712
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
[TBL] [Abstract][Full Text] [Related]
8. Use of Sodium-Glucose Cotransporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real-World Data.
Alonso A; Morris AA; Naimi AI; Alam AB; Li L; Subramanya V; Chen LY; Lutsey PL
J Am Heart Assoc; 2024 Mar; 13(6):e032783. PubMed ID: 38456406
[TBL] [Abstract][Full Text] [Related]
9. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
Fu EL; Patorno E; Everett BM; Vaduganathan M; Solomon SD; Levin R; Schneeweiss S; Desai RJ
Eur Heart J; 2023 Jun; 44(24):2216-2230. PubMed ID: 37259575
[TBL] [Abstract][Full Text] [Related]
11. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure.
Hofer F; Kazem N; Richter B; Sulzgruber P; Schweitzer R; Pailer U; Hammer A; Koller L; Hengstenberg C; Niessner A
Cardiovasc Drugs Ther; 2022 Jun; 36(3):497-504. PubMed ID: 34342791
[TBL] [Abstract][Full Text] [Related]
12. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
[TBL] [Abstract][Full Text] [Related]
13. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
14. Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study.
Hsiao FC; Lin CP; Tung YC; Chang PC; McMurray JJV; Chu PH
Int J Cardiol; 2021 May; 330():91-97. PubMed ID: 33587940
[TBL] [Abstract][Full Text] [Related]
15. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
Sartipy U; Dahlström U; Fu M; Lund LH
JACC Heart Fail; 2017 Aug; 5(8):565-574. PubMed ID: 28711451
[TBL] [Abstract][Full Text] [Related]
16. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
[TBL] [Abstract][Full Text] [Related]
17. Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum: Phenotyping, and Prognostic and Therapeutic Implications.
Stolfo D; Uijl A; Vedin O; Strömberg A; Faxén UL; Rosano GMC; Sinagra G; Dahlström U; Savarese G
JACC Heart Fail; 2019 Jun; 7(6):505-515. PubMed ID: 31146874
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure.
Savarese G; Vedin O; D'Amario D; Uijl A; Dahlström U; Rosano G; Lam CSP; Lund LH
JACC Heart Fail; 2019 Apr; 7(4):306-317. PubMed ID: 30852236
[TBL] [Abstract][Full Text] [Related]
19. Safety of continuing mineralocorticoid receptor antagonist treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: Data from Swedish Heart Failure Registry.
Guidetti F; Lund LH; Benson L; Hage C; Musella F; Stolfo D; Mol PGM; Flammer AJ; Ruschitzka F; Dahlstrom U; Rosano GMC; Braun OÖ; Savarese G
Eur J Heart Fail; 2023 Dec; 25(12):2164-2173. PubMed ID: 37795642
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium-glucose cotransporter 2 inhibitors.
Marques P; Matias P; Packer M; Vieira JT; Vasques-Nóvoa F; Sharma A; Mavrakanas TA; Friões F; Ferreira JP
Eur J Heart Fail; 2023 Dec; 25(12):2191-2198. PubMed ID: 37559543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]